Barclays
ATXI

Barclays’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Barclays’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1
Closed -$2K – 4825
2021
Q3 		$2K Sell
1
-1
-50% -$2.07K ﹤0.01% 4681
2021
Q2 		$5K Sell
2
-3
-60% -$14.8K ﹤0.01% 4752
2021
Q1 		$34K Buy
5
+3
+150% +$20.6K ﹤0.01% 4280
2020
Q4 		$13K Sell
2
-1
-33% -$5.24K ﹤0.01% 4730
2020
Q3 		$33K Hold
3
– – ﹤0.01% 4774
2020
Q2 		$39K Buy
+3
New +$33.8K ﹤0.01% 5028
2019
Q4 		– Hold
0
– – – 6897
2019
Q3 		– Hold
0
– – – 7214
2019
Q2 		– Hold
0
– – – 7349
2019
Q1 		– Hold
0
– – – 7393

Other funds holding ATXI

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return

Barclays's ATXI Position: Q4 2021 in Review

Barclays sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q4 2021, closing a stake of 1 share — an estimated $2K sold.

Barclays first reported a position in ATXI in Q2 2020 and held it in 6 quarters. The position peaked at $39K in Q2 2020. 14 funds tracked by Wall St. Rank hold ATXI as of Q4 2021.

  • Barclays reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Barclays sold 1 Avenue Therapeutics, Inc. Common Stock share in Q4 2021, an estimated $2K.
  • Barclays first reported a position in Avenue Therapeutics, Inc. Common Stock in Q2 2020 and held it in 6 quarters.
  • Barclays's Avenue Therapeutics, Inc. Common Stock position peaked at $39K in Q2 2020.
  • 14 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.